Oxford Immunotec signed distributor agreement with RIKEN Genesis for T-SPOT Discovery SARS-CoV-2 Kit in Japan
On Dec. 2, 2020, Oxford Immunotec announces an exclusive distribution agreement with RIKEN Genesis in Japan. Under the…
On Dec. 2, 2020, Oxford Immunotec announces an exclusive distribution agreement with RIKEN Genesis in Japan. Under the…
On Dec. 2, 2020, the first COVID-19 vaccine for the UK, developed by Pfizer/BioNTech, was given approval for…
On Dec. 2, 2020, Codex DNA announced the release of seven new synthetic SARS-CoV-2 genomes for use in…
On Dec. 2, 2020, Eli Lilly announced that the U.S. government had purchased 650,000 additional doses of the…
On Dec. 2, 2020, BD (Becton, Dickinson) announced plans to invest approximately $1.2 billion over a 4-year period…
On Dec. 2, 2020, Pfizer and BioNTech announced that the Medicines & Healthcare Products Regulatory Agency (MHRA) in…
On Dec. 1, 2020, Pfizer and BioNTech announced they had submitted on Nov. 30, 2020, a formal Application…
On Nov. 25, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes…
On Nov. 30, 2020, Jaguar Health subsidiary, Napo Pharmaceuticals, announced that Jaguar and Napo are planning to develop…
On Nov. 30, 2020, Mateon Therapeutics announced that the India arm of ARTI-19 global study was on track…
On Nov. 30, 2020, the City of Hope reported that its investigational vaccine produced strong protective immunity against…
On Nov. 30, 2020, Innovation Pharmaceuticals announced additional independent preliminary laboratory research suggests Brilacidin, the Company’s flagship defensin…
On Nov. 29, 2020, Moderna announced a supply agreement with the United Kingdom (UK) government for an additional…
On Nov. 27, 2020, SmartPharm Therapeutics, a wholly-owned subsidiary of Sorrento Therapeutics, announced that it had been awarded…
On Nov. 27, 2020, the U.S. Department of Agriculture (USDA) announced that it had confirmed cases of SARS-CoV-2…
On Nov. 25, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes…
On Nov. 25, 2020, RedHill Biopharma announced partnerships with two leading, U.S.-based manufacturers for large-scale manufacturing of opaganib….
On Nov. 25, 2020, AIM ImmunoTech announced that Roswell Park Comprehensive Cancer Centerï¾’s Phase 1/2a study evaluating the…
On Nov. 25, 2020, Moderna announced that the European Commission (EC) has approved an agreement to secure 80…
On Nov. 25, 2020, Altimmune announced that it had submitted an Investigational New Drug (IND) application to the…
On Nov. 25, 2020, BioNTech and Shanghai Fosun Pharmaceutica jointly announced that their lead mRNA COVID-19 vaccine candidate…
On Nov. 24, 2020, RELIEF THERAPEUTICS announced that more than 175 patients with Critical COVID-19 and Respiratory Failure…
On Nov. 24, 2020, MediciNova announced development progress on its intranasal SARS-CoV-2 vaccine for COVID-19 utilizing BC-PIV, a…
On Nov. 24, 2020, Northwestern University researchers announced they had developed a new artificial intelligence (A.I.) platform that…
On Nov. 24, 2020, published data from researchers at Mayo Clinic found that physical separation reduced the exposure…
On Nov. 24, 2020, Todos Medical announced that it has completed the installation of Tecan’ laboratory automated equipment…
On Nov. 23, 2020, the University of Oxford, in collaboration with AstraZeneca, announced interim trial data from its…
On Nov. 23, 2020, AstraZeneca announced positive high-level results from an interim analysis of clinical trials of AZD1222…
On Nov. 23, 2020, Bellerophon Therapeutics announced that the independent Data Monitoring Committee (DMC) had completed its pre-specified…
On Nov. 23, 2020, CytoDyn announced it had reached enrollment of 293 patients in its Phase 3 trial…